List view / Grid view
16 June 2015 | By Victoria White
The first paediatric patient has begun treatment in Genzyme’s Phase 1/2 clinical trial focused on evaluating the investigational therapy olipudase alfa...
15 June 2015 | By
The US Food and Drug Administration (FDA) has accepted for review Teva’s Biologics License Application (BLA) for reslizumab...
15 June 2015 | By Cherwell Laboratories
Cherwell aids additional training opportunities for cleanroom biodecontamination...
15 June 2015 | By Victoria White
CPhI has announced the opening of the annual CPhI Pharma Awards for 2015 – with five new categories covering the entire pharmaceutical supply chain...
15 June 2015 | By Victoria White
CTI BioPharma has announced findings from a Phase 2 trial of tosedostat in combination with low dose cytarabine in patients with acute myeloid leukaemia...
15 June 2015 | By Victoria White
Analyses of Celgene’s MCL-002 study, comparing Revlimid with investigators' choice in MCL, were presented at the European Haematology Association congress...
15 June 2015 | By Victoria White
More than 60,000 Australians are estimated to have reduced or discontinued their use of prescribed statins following the airing of a TV programme...
15 June 2015 | By Victoria White
A Phase I/IIa study of NTCELL, an regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease, has met its endpoints...
15 June 2015 | By Victoria White
AstraZeneca presented results from its Phase III trial investigating lesinurad in combination with febuxostat in patients with tophaceous gout at EULAR 2015...
15 June 2015 | By Victoria White
UCB has announced data from a Phase 3 study that showed the substantial benefits, at 52 weeks, of adding Cimzia to optimised methotrexate treatment...
12 June 2015 | By Victoria White
Results from a new study show that the chickenpox vaccine can be safe even in children with rheumatic disease receiving immunosuppression treatment...
12 June 2015 | By
Celgene International has announced updated results of its pivotal Phase III FIRST trial of REVLIMID at the European Haematology Association annual congress...
12 June 2015 | By Victoria White
Novartis has presented promising data from the Phase III COMPLEMENT 2 study of Arzerra in patients with replapsed chronic lymphocytic leukaemia...
12 June 2015 | By Victoria White
New analyses from pivotal Phase III studies show Xolair helps patients with Chronic Spontaneous Urticaria achieve improvements in quality of life measures...
12 June 2015 | By Victoria White
Top line results from a Phase 3 study evaluating Pristiq in paediatric patients with Major Depressive Disorder (MDD) have been announced...
